Peer-influenced content. Sources you trust. No registration required. This is HCN.

MedPage TodayAdjuvant Anti-PD-1 Misses on OS in High-Risk Melanoma

Dr. Kenneth Grossmann commented after presenting the results at the ASCO Annual Meeting in June: “The overall survival impact of pembrolizumab was likely influenced by effective post-relapse treatment, with standard-of-care patients receiving PD-1 blockade.” Dr. Grossmann then concluded that “single-agent anti-PD-1 antibody treatment should be a standard-of-care option for adjuvant treatment of high-risk resected melanoma,” and offered that the OS “trend of benefit is there.”

The Healthcare Communications Network is owned and operated by IQVIA Inc.

Click below to leave this site and continue to IQVIA’s Privacy Choices form